Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
复制标题
DOI：
10.1038/s41598-022-19780-7
复制
发表时间：
2022-09-15
影响因子：
4.6
通讯作者：
Allen, Robert D.
中科院分区：
文献类型：
--
作者：
Cao, Xia;Maruyama, Junki;Zhou, Heyue;Fu, Yanwen;Kerwin, Lisa;Powers, Colin;Sattler, Rachel A.;Manning, John T.;Singh, Alok;Lim, Reyna;Healy, Laura D.;Johnson, Sachi;Cabral, Elizabeth Paz;Li, Donghui;Lu, Lucy;Ledesma, Arthur;Lee, Daniel;Richards, Susan;Rivero-Nava, Laura;Li, Yan;Shen, Weiqun;Stegman, Karen;Blair, Benjamin;Urata, Shinji;Kishimoto-Urata, Magumi;Ko, Jamie;Du, Na;Morais, Kyndal;Lawrence, Kate;Rivera, Ianne;Pai, Chin-, I;Bresson, Damien;Brunswick, Mark;Zhang, Yanliang;Ji, Henry;Paessler, Slobodan;Allen, Robert D.
2019冠状病毒病（COVID-19）继续对全球人口产生重大影响，因此，能够快速开发针对SARS-CoV-2变体的治疗方法的对策平台至关重要。我们报告使用噬菌体展示人抗体库的方法，以快速确定中和抗体（nAbs）对SARS冠状病毒2。我们证明了两种nAb STI-2020和STI-5041对SARS-CoV-2 WA-1毒株以及α和β变体的结合和中和能力。当在用WA-1菌株或β变体攻击的COVID-19金黄（叙利亚）仓鼠模型中静脉内或鼻内给药时，STI-2020和STI-5041具有保护作用。静脉内和鼻内施用nAb的能力可能具有重要的治疗意义，并且1期健康受试者临床试验正在进行中。
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.
登录
查看更多内容
DOI：
10.1152/ajplung.00173.2001
发表时间：
2002-04-01
影响因子：
4.9
作者：
Southam, DS;Dolovich, M;Inman, MD
通讯作者：
Inman, MD
影响因子：
32.4
作者：
Hoagland DA;Møller R;Uhl SA;Oishi K;Frere J;Golynker I;Horiuchi S;Panis M;Blanco-Melo D;Sachs D;Arkun K;Lim JK;tenOever BR
通讯作者：
tenOever BR
影响因子：
7.3
作者：
Hamming, I;Timens, W;van Goor, H
通讯作者：
van Goor, H
影响因子：
20.1
作者：
Donoghue, M;Hsieh, F;Acton, S
通讯作者：
Acton, S
影响因子：
158.5
作者：
Gupta, Anil;Gonzalez-Rojas, Yaneicy;Shapiro, Adrienne E.
通讯作者：
Shapiro, Adrienne E.